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Background: Several antibiotics have shown promising anti-malarial effects and have been useful for malarial
chemotherapy, particularly in combination with standard anti-malarial drugs. Tigecycline, a semi-synthetic derivative
of minocycline with a unique and novel mechanism of action, is the first clinically available drug in a new class of
glycylcycline antibiotics.
Methods: Tigecycline was tested in vitro against chloroquine (CQ)-sensitive (D6) and resistant strains (W2) of
Plasmodium falciparum alone and in combination with CQ. Tigecycline was also tested in vivo in combination with
CQ in Plasmodium berghei-mouse malaria model for parasitaemia suppression, survival and cure of the malaria
infection.
Results: Tigecycline was significantly more active against CQ-resistant (W2) than CQ-susceptible (D6) strain of
P. falciparum. Tigecycline potentiated the anti-malarial action of CQ against the CQ-resistant strain of P. falciparum
by more than seven-fold. Further, treatment of mice infected with P. berghei with tigecycline (ip) produced significant
suppression in parasitaemia development and also prolonged the mean survival time. Treatment with as low as
3.7 mg/kg dose of tigecycline, once daily for four days, produced 77-91% suppression in parasitaemia. In vivo treatment
with tigecycline in combination with subcurative doses of CQ produced complete cure in P. berghei-infected mice.
Conclusion: Results indicate prominent anti-malarial action of tigecycline in vitro and in vivo in combination with CQ
and support further evaluation of tigecycline as a potential combination candidate for treatment of drug-resistant cases
of malaria.
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Malaria continues to be the major global health problem
and a leading cause of deaths [1]. According to recent
WHO estimates, in 2012 there were an estimated 207
million cases of malaria and approximately 627,000
malaria deaths. An estimated 3.4 billion people continue
to be at risk of malaria, mostly in Africa and Southeast
Asia. Around 80% of malaria cases occur in Africa.
Inappropriate treatment or use of chemoprophylaxis,
delays in diagnosis or care-seeking, infections with* Correspondence: btekwani@olemiss.edu
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unless otherwise stated.drug-resistant Plasmodium falciparum and non-immunity
of the individuals exposed to the malaria infection have
been identified as important risk factors for malaria-related
deaths in individuals living in or travelling to malaria-
endemic countries [2]. The spreading of resistance of
P. falciparum to existing drugs, and recent reports on
artemisinin resistance intensify the need for new anti-
malarial agents [3-5]. Antibiotics with anti-malarial activity,
in combination with traditional anti-malarial drugs, are
potentially useful options for drug-resistant cases of
malaria [6,7]. Several antibiotics have shown promising
anti-malarial effects and may be useful for malarial
chemotherapy in combination with standard anti-malarial
drugs [8,9]. Particularly, tetracycline with quinine or
artesunate are considered potential second-line therapyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[10]. A few recent reports have indicated the anti-malarial
properties of tigecycline [11-13]. Tigecycline belongs to a
new class of glycylcycline tetracycline derivatives with
broad-spectrum, anti-infective activities. Glycylcyclines
contain glycyl amido substitutions at position 9 (Figure 1).
Tigecycline, the 9-t-butylglycylamido derivative of
minocycline, is the first marketed compound of this
new class of antibiotics [14]. Its increased affinity for the
ribosome yields more potent inhibition of prokaryotic
protein biosynthesis compared to other tetracyclines [15],
and this is thought to be the basis of tigecycline’s
improved antibacterial spectrum, including activity against
multidrug-resistant species. Tigecycline was found to
act faster against Plasmodium than any of the other
antibiotics tested [13]. It was also tested against clinical
isolates of P. falciparum from Gabon [11] and the Brazilian
Amazon [12]. These studies demonstrate the potential of
tetracycline derivatives in the development of improved
anti-malarials. The anti-malarial efficacy of tigecycline was
evaluated in vitro against chloroquine (CQ)-sensitive and
CQ-resistant strains of P. falciparum and also in vivo in
Plasmodium berghei-mouse model.
Methods
In vitro anti-malarial parasite lactate dehydrogenase assay
Anti-malarial activity was determined in vitro on
CQ-sensitive (D6, Sierra Leone) and -resistant (W2,
Indochina) strains of P. falciparum. The 96-well microplate
assay is based on evaluation of the effect of the compounds
on growth of asynchronous cultures of P. falciparum,Figure 1 Structures of (A) tetracycline, (B) minocycline,
(C) tigecycline.determined by the assay of parasite lactate dehydrogenase
(pLDH) activity [16]. The appropriate dilutions of the
drugs were prepared in DMSO or RPMI-1640 medium and
added to the cultures of P. falciparum (2% haematocrit, 2%
parasitaemia) set up in clear, flat-bottomed, 96-well plates.
The plates were placed into the humidified chamber and
flushed with a gas mixture of 90% N2, 5% CO2 and 5% O2.
The cultures were incubated at 37°C for 48–120 hours.
Growth of the parasite in each well was determined by
pLDH assay using Malstat® reagent as described earlier
[17]. The anti-malarial antibiotics, which are known to act
through inhibition apicoplast’s protein biosynthesis [18,19],
induce delayed death of the malaria parasite [20]. The
in vitro anti-malarial activity of tigecycline and other related
antibiotics was also determined at intervals over an
extended time period (120 hours) of exposure. The
medium and red blood cell (RBC) controls were also set
up in each plate. The standard anti-malarial agents, CQ
and artemisinin, were used as the positive controls,
while DMSO was tested as the negative control. The
anti-malarial efficacy (expressed as IC50 and IC90 values)
was determined by the dose response analysis with XLfit©.
In vitro drug combination anti-malarial assay
The potential interactions of tigecycline and CQ were
assessed by a ‘chequerboard’ assay design. Serial dilutions
of the drugs were prepared in a 96-well plate and tested
on non-synchronous parasite cultures. Combination
effects were then measured using the pLDH assay for
96 hours as described above [17]. The IC50s were calculated
for each drug alone and with criss-cross dilutions of the
partner drug in both D6 and W2 P. falciparum strains.
In vivo anti-malarial assay
The in vivo anti-malarial activity of tigecycline alone and
combination with CQ was determined by a combined
four days’ treatment suppressive-curative-survival assay
described earlier [21] in mice infected with P. berghei
(NK65). The protocol for in vivo anti-malarial evaluation
has been approved by the University of Mississippi
Institutional Animal Care and Use Committee (IACUC).
Male mice (Swiss Webster strain) from HARLAN with
18–20 g body weight were intraperitoneally inoculated
with 4 × 107 parasitized RBCs obtained from a highly
infected donor mouse. Mice were divided into different
groups with five mice in each group. Tigecycline was
prepared in vehicle (DMSO: Tween-80: PEG-400: water,
added sequentially with ratio of 10:0.5: 40:49.5) and CQ
was prepared in sterile 0.9% saline. Mice were treated
once daily for four days with different doses of CQ (po
through oral gavage) and/or tigecycline (ip) about four
hours after the infection. Tigecycline was also tested in
divided doses, each dose was administered about six hours
apart. For combination treatment studies, the mice were
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about two hours. The test drugs were administered to the
mice once a day for four consecutive days (days 0 to 3). A
control group was treated with an equal volume of vehicle.
The mice were closely observed after every dose for any
signs of toxicity. The body weights were recorded
once daily. Blood smears were prepared on different
days starting at five days’ post-infection (until day 28
post-infection) by tail snip, stained with Giemsa and
observed under a microscope for determination of
parasitaemia. Mice without parasitaemia until day 28
post-infection were considered as cured. Also, suppression
in development of parasitaemia was computed by
comparing the parasitaemia in control vehicle-treated
group and groups treated with test drug or combinations.
The mean survival time was also computed for con-
trol and treated groups. The results are presented as
parasitaemia suppression of day 5 post-treatment, mean
survival time of mice in each group, cure and survival
graphs computed by Prism 6.0.
Results
In vitro anti-malarial activity of tigecycline and other
related tetracycline antibiotics
The anti-malarial efficacy of tigecycline and other related
antibiotics, namely tetracycline and minocycline, was
evaluated in vitro against CQ-susceptible (Indochina D6)
and CQ-resistant (Sierra Leone W2) strains of P. falciparum
(Table 1). The parent antibiotic tetracycline did not show
any anti-malarial activity against D6 and W2 P. falciparum
strains up to 100 mM concentration, while minocycline and
tigecycline both showed time-dependent activity. The
inhibition of P. falciparum growth by minocycline was
faster compared to that by tigecycline. Considering
the trend on anti-malarial efficacy, both minocycline
and tigecycline were more active against CQ-resistant
W2 strain compared to that against CQ-sensitive D6
strain. However, the difference in activity against D6
and W2 strains was much more prominent in the
case of tigecycline compared to that by minocycline.
Tigecycline exhibited delayed P. falciparum growth








D6 W2 D6 W2
48 >100 79.7 ± 20.1 >100 >100
72 49.7 ± 1.5 23.3 ± 2.1* >100 >100
96 30.7 ± 2.5 22.0 ± 0.3* 94.3±2.1 89.7 ± 0.6
120 23.3 ± 0.6 12.2 ± 3.1* 88.6±1.5 87.6 ± 4.1
Values are mean ± SD of at least three observations.
*-Statistically significant difference (p value <0.05) compared to corresponding activwhile the trend of inhibition of P. falciparum growth with
minocycline and CQ was similar with lowest IC50 values
at 72 hours, which remained constant until 120 hours.
In vitro anti-malarial activity of tigecycline in combination
with chloroquine
Further tigecycline was also tested against P. falciparum D6
and W2 strains in combination with varying concentrations
of CQ (Figure 2). The results obtained with the combina-
tions with higher concentrations of CQ (>50 nM for D6
and >250 nM for W2) and tigecycline (>3.12 mM for both
D6 and W2 strains) could not be analysed by the dose
response for determination of IC50 values due to additive
activities at higher doses. The IC50 of CQ against both D6
and W2 P. falciparum strains in presence of low concentra-
tions (<3.13 mM) of tigecycline were analysed. The IC50 for
CQ against D6 CQ-S strain did not change significantly in
presence 0.78 mM tigecycline (0 vs 0.78 p value 0.212).
However, the activity of CQ was marginally but significantly
improved against D6 CQ-S strain at 1.56 and 3.13 mM
tigecycline (0 vs 1.56 p value 0.05, 0 vs 3.13 p value
0.0388). In contrast, tigecycline produced > seven-fold
potentiation of activity of CQ against CQ-R W2 strain of
P. falciparum (p value <0.0001), even at the lowest con-
centration tested (0.78 mM) for tigecycline. Tigecycline
alone at 0.78-6.25 mM concentrations did not show any
noticeable effect on D6 and W2 P. falciparum strains.
In vivo anti-malarial activity of tigecycline in Plasmodium
berghei-mice malaria model
Anti-malarial activity of tigecycline was tested in vivo in
P. berghei mouse malaria model for parasitaemia sup-
pression, survival and cure of the infection (Table 2,
Figures 3 and 4). CQ was run as a positive control
and also in combination with tigecycline. A control
group of mice were treated with the vehicle only. The
mice in this group developed significant parasitaemia
(8-12%) on day 5 post-infection. The level of parasitaemia
marginally declined to (7-9%) on day 7 and increased
continuously, resulting in 100% mortality by day 15–20
(MST-12.8 ± 2.3 days). In view of poor bioavailability of





D6 W2 D6 W2
56.7 ± 5.7 40.5 ± 8.58 208.3 ± 10.4 466.0 ± 31.2*
29.9 ± 0.6 25.9 ± 3.08 79.5 ± 0.5 419.0 ± 45.6*
19.2 ± 2.2 19.1 ± 0.7 79.7 ± 1.5 402.0 ± 2.1*
27.8 ± 2.4 21.7 ± 1.2 89.7 ± 3.1 397.0 ± 8.1*
ity against D6 strain.
Figure 2 In vitro activity of chloroquine on CQ-susceptible (D6)
and -resistant (W2) strains of Plasmodium falciparum in
combination with tigecycline. Values are mean ± SD of three values.
Table 2 Anti-malarial activity of tigecycline in








Vehicle - - 0/5 12.8±2.3
CQ 11.1 >99.99 0/5 >28
33.3 >99.99 0/5 >28
100 >99.99 0/5 >28
TG 3.7 77.7 ± 9.5 0/5 15.2 ± 2.9
11.1 93.6 ± 2.7 0/5 >28
33.3 97.3 ± 1.2 0/5 >28
100 97.6 ± 0.9 0/5 >28
TG (DD)* 3.7 91.80 ± 3.7 0/5 16.0 ± 3.7
11.1 96.3 ± 1.7 0/5 >28
33.3 98.7 ± 0.9 0/5 >28
100 98.1 ± 0.5 0/5 >28
CQ + TG 33.3 + 3.7 >99.99 1/5 >28
33.3 + 11.1 >99.99 3/5 >28
33.3 + 33.3 >99.99 5/5 >28
33.3 + 100 >99.99 5/5 >28
*(DD)- Divided dose with two split doses six hours apart; 1Parasitaemia
suppression – Per cent suppression of parasitaemia on day 5 post-treatment
compared to vehicle control; >99.99% suppression - no detectable parasitaemia;
2Cure number of mice with no detectable parasitaemia until day 28; 3MST - mean
survival time; MST >28 - all mice in the group survived until day 28 and were
euthanized at the end of the study; The data are mean ± SD> of five animals.
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formulated vehicle (DMSO: Tween-80: PEG 400:
water, added sequentially with ratio of 10:0.5: 40:49.5).
This formulation was standardized to achieve maximum
solubilization of the drug to ensure its optimum bioavail-
ability in vivo. Tigecycline was tested at four dose levels
(3.7, 11.1, 33.3 and 100 mg/kg/day) with two different
regimens. The first regiment was similar to the control
drug CQ, once daily for four days at the doses specified in
individual experiments. In another regimen, the daily
dose was divided into two equal doses, which were
administered six hours apart by the ip route. None of
treatment regimens and the dose levels tested for
tigecycline produced any noticeable toxic effects in
mice. Tigecycline once daily and in divided dose
showed similar results regarding suppression of
P. berghei infection in mice. Interestingly, even the
lowest dose of 3.7 mg/kg produced a 77% suppression
in parasitaemia on day 5 after the treatment (Table 2
and Figure 3B), and 91% suppression in case of split
dose regimen (Table 2 and Figure 3C). However, thelow dose of 3.7 mg/kg did not have significant effect
on the overall survival or the mean survival time
(Table 2 and Figure 4). The level of parasitaemia in
mice from these groups recorded on day 14 was also
similar to the mice in control vehicle-treated group
(Figure 3B and 3C). The control anti-malarial drug
CQ produced almost complete suppression in parasitaemia
at all the doses (11.1, 33.3 and 100 mg/kg) tested (Table 2).
Further, development of parasitaemia in mice from all the
CQ-treated groups was significantly delayed (Figure 3A)
and the mice in all three CQ-treated group remained alive
till 28 days post-infection/treatment (Table 2, Figure 4A)
and were euthanized. Higher doses of tigecycline pro-
duced >95% suppression in parasitaemia. A rise in the
level of parasitaemia was noticed in groups of mice
treated with 11.1 and 33.3 mg/kg after ten days post-
treatment/infection. The level of parasitaemia in mice
treated with 11.1 mg/kg tigecycline reached the level
comparable to the control vehicle-treated group by
day 28 post-treatment, while the parasitaemia levels
in mice treated with 33.3 mg/kg tigecycline remained
low, about 50% lower compared to the vehicle treated
group at day 28. Interestingly, the higher dose groups,
which showed traces of parasitaemia on day 5 and 7
(<0.5%), became free from parasitaemia and remained
Figure 3 Progress of parasitaemia in Plasmodium berghei-infected mice treated with [A] chloroquine (CQ); [B] tigecycline (TG) once
daily dose; [C] tigecycline (TG) split dose; and, [D] combination of tigecycline (TG) and chloroquine (CQ). Each point represent value
mean ± SD of five mice or the number of mice remaining live at that point of time. The numbers shown along each graph show the daily dose
of the specified drug. The mice were treated daily with dose of the drug indicated, for four days staring from day 0 (within 1–2 hours after
inoculating the mice with P. berghei parasitized erythrocytes. Additional details are described in Methods.
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experiment). The mice in these groups (100 mg/kg
tigecycline single or split dose) were considered cured.
Tigecycline was also tested in combination with
suboptimal dose of CQ (33.3 mg/kg). Treatment ofFigure 4 Survival pattern of Plasmodium berghei-infected mice treate
[C] tigecycline (TG) split dose; and, [D] combination of tigecycline (TGmice with this dose of CQ, though displaying almost
complete suppression of parasitaemia on day 5, was
not cured. The parasitaemia in mice from this group
rose from day 10 and increased continuously till ter-
mination of the experiment on day 28 post-treatmentd with [A] chloroquine (CQ); [B] tigecycline (TG) once daily dose;
) and chloroquine (CQ).
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line showed a significantly higher anti-malarial effect.
At a dose as low as 3.7 mg/kg of tigecycline,
33.3 mg/kg CQ significantly delayed parasitaemia
development and produced 20% cure (Figure 3D and
Table 2). The co-treatment with 11.1 mg/kg tigecycline
in combination with 33.3 mg/kg CQ dose cured 60% of
mice (Table 2), and the development of parasitaemia was
markedly suppressed in the remaining mice in group
(Figure 3D). Treatment with 33.3 and 100 mg/kg tige-
cycline in combination with 33.3 mg/kg CQ produced
100% cures (Table 2). None of the combination doses
showed any noticeable adverse effects in mice.
Discussion
Use of antibiotics in combination with standard anti-
malarial drugs has been an important approach for
treatment of drug-resistant, uncomplicated as well as
complicated cases of malaria [22]. Antibiotic treatment has
been shown to prevent development of malaria infection,
and also showed long-term protection in mice against
subsequent malaria infections [23]. Prescription of antibi-
otics in patients with presumed malaria associated febrile
illness is high [24]. Doxycycline, a tetracycline antibiotic, is
one of the most prescribed, effective and affordable
anti-malarial antibiotics [9]. Although it is a slow-acting
blood-schizontocide, it is safe and highly effective for
treatment of malaria, when used in combination with a
fast-acting anti-malarial drug. The anti-malarial use of
doxycycline is especially suitable in areas with CQ and
multidrug-resistant P. falciparum malaria. However,
doxycycline confers only partial protection against the
sporozoite-induced malaria infections and also use of
doxycycline is not recommended for pregnant women
and children under eight years of age [9]. Considering the
proven records of safety and efficacy, tetracycline antibiotics
with appropriate pharmacokinetic and pharmacodynamic
profiles should be suitable for inclusion in new combination
regimens for treatment of malaria. Attempts to acquire
resistance against minocycline in experimental mouse
malaria models suggested a slower development of
resistance compared to other standard anti-malarial drugs
[25]. Recently, in an attempt to optimize anti-malarial
efficacy of tetracycline several seven-position modified
tetracycline analogues were identified with improved anti-
malarial activity in vitro against P. falciparum and in vivo
in mouse malaria models [26]. Tigecycline is actually a
glycylcycline derivative of minocycline, the first clinically
approved for treatment of skin and soft tissue infections,
as well as intra-abdominal infections. Recent reports
regarding prominent activity of tigecycline against
several field isolates of P. falciparum [11-13] prompted the
evaluation of this antibiotic in vitro against CQ-susceptible
and -resistant strains of P. falciparum in combination withCQ. Tigecycline was found to be significantly more
active against the resistant P. falciparum strain than
the susceptible. Further, low concentrations of tigecycline
markedly and selectively sensitized the CQ-resistant (W2)
strains to CQ action. It would be interesting to understand
the mechanism for more prominent action of tigecycline
against CQ-resistant strains and also potentiation of CQ
action against resistant strains. Compared to earlier reports
on delayed death of the malaria parasites with antibiotics
[6,20,27], tigecycline seems to show faster anti-malarial
action in vitro. However, in vitro activity of tetracycline
observed in this activity was low compared to that reported
earlier [27]. This may be due delayed death of the parasite
by tetracycline. Significant inhibition of P. falciparum
growth was noticed even with 24-hour exposure of P.
falciparum culture. A proteomic study with in vitro cul-
ture of P. falciparum schizonts treated with doxycycline
indicated significant changes in mitochondria and apico-
plast proteomes as distinct characteristic for antimalarial
action of this antibiotic [28]. Tigecycline inhibits protein
synthesis by binding to the 30S ribosomal subunit of
bacteria and blocks entry of aminoacyl-tRNA into the A
site of the ribosome during prokaryotic translation [15].
Tigecycline inhibits the initial codon recognition step
of tRNA accommodation and prevents rescue by the
tetracycline-resistance protein TetM [15]. It would inter-
esting to know the mechanism for anti-malarial action of
tigecycline. In vivo in the P. berghei mouse malaria model,
treatment with very low doses (3.7 mg/kg) of tigecycline
cause significant suppression of parasitaemia, while treat-
ment with high dose of tigecycline (100 mg/kg) resulted in
complete cures. Tigecycline also markedly potentiated the
anti-malarial action of CQ in vivo.
Tigecycline is administered intravenously in the clinic,
and its clinical use for treatment of malaria may be lim-
ited. The results presented here show prominent anti-
malarial action of tigecycline when administered through
ip route. This suggests that pharmacokinetic barriers
might be overcome with a better understanding of the
barrier transport mechanisms. Pharmacokinetic and
pharmacodynamic properties of glycylcycline tetracycline
antibiotics have not been widely evaluated, although some
progress has been during recent clinical evaluations of
tigecycline [29]. Further optimization of pharmacokinetic
and pharmacodynamic properties of tigecycline through
structural modifications or pharmaceutical formulations
to improve its bioavailability may afford a faster route for
discovery of a new anti-malarial drug.
Conclusions
Tigecycline, a glycylcycline antibiotic, showed prominent
anti-malarial activity in vitro against P. falciparum and
in vivo against P. berghei infection in mice. The anti-
malarial activity of tigecycline was significantly higher
Sahu et al. Malaria Journal 2014, 13:414 Page 7 of 7
http://www.malariajournal.com/content/13/1/414against CQ-resistant (W2) than against -susceptible
(D6) P. falciparum strain. Also, tigecycline selectively
potentiated the anti-malarial action of CQ against
CQ-resistant P. falciparum strain. Treatment of mice
infected with P. berghei daily for four days with as
low as 3.7 mg/kg dose of tigecycline resulted into 77-91%
suppression in parasitaemia. Treatment with tigecycline in
combination with subcurative dose of CQ resulted into
complete cure of malaria in P. berghei-infected mice. This
is the first report demonstrating in vivo anti-malarial
activity of a new class of glycylcycline antibiotic. This
in vivo non-clinical study is a logical extension of recent
reports regarding in vitro sensitivity of some field and
laboratory isolates of P. falciparum against tigecycline.
Results indicate potential for optimization and application
of glycylcycline antibiotics in combination with standard
anti-malarial drugs for treatment of drug-resistant malaria
infections.
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